Blueprint Medicines Corporation
BPMC
Helyezés a részvények között
#2361
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Részvényárfolyam
$129.46
Utolsó szinkronizálás: 2025-07-18
Piaci kapitalizáció
$8.36B
Változás (1 nap)
0.00%
Változás (1 év)
0.00%
Ország
US
Kereskedés Blueprint Medicines Corporation (BPMC)
Kategória
Healthcare
Bevétel a(z) Blueprint Medicines Corporation (BPMC) részvényhez
Bevétel ekkor: Mar 2025 TTM: $562.12M
Blueprint Medicines Corporation legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $562.12M. 2023 évben a vállalat $249.38M árbevételt ért el, amely növekedés a 2022 évben elért $204.04M árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Blueprint Medicines Corporation bevételtörténete 2013 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $562.12M | 10.47% |
| 2024 | $508.82M | 104.04% |
| 2023 | $249.38M | 22.22% |
| 2022 | $204.04M | 13.30% |
| 2021 | $180.08M | -77.31% |
| 2020 | $793.74M | 1,093.37% |
| 2019 | $66.51M | 49.39% |
| 2018 | $44.52M | 107.79% |
| 2017 | $21.43M | -22.85% |
| 2016 | $27.77M | 143.61% |
| 2015 | $11.40M | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| $12.62B | 2,145.84% |
US
|
|
| $2.23B | 296.36% |
US
|
|
| $15.74B | 2,700.88% |
AU
|
|
| $6.02B | 971.17% |
NL
|
|
| - | - |
CH
|
